SCHEMBL1102274

SCHEMBL1102274

CCCCc1ccc(-c2cccc(NN)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.44
▸ RARB P10826 5/20 0.44
▸ TRPV1 Q8NER1 1/20 0.42
▸ MAOB P27338 4/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.41
▸ RARA P10276 1/20 0.40
▸ RARG P13631 1/20 0.40
▸ TSHR P16473 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ MMP2 P08253 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1091596 0.98 HSD11B1 (0.43) HSD11B1RARBTRPV1MAOBTAAR1
SCHEMBL1091891 0.82 CYP19A1 (0.53) HSD11B1RARBMAOBTAAR1TSHR
SCHEMBL11106036 0.82 LPL (0.45) TRPV1
Hydrochloric Acid SCHEMBL4613152 0.81 HSD11B1 (0.41) HSD11B1RARBTRPV1MAOBTAAR1
SCHEMBL1229928 0.77 HPGD (0.51) HSD17B10SMN1; SMN2NPC1RAB9ACA2
SCHEMBL25956648 0.77 HSD11B1 (0.53) HSD11B1RARBRARARARGTSHR
SCHEMBL10793241 0.77 LPL (0.51) —
Hydrochloric Acid SCHEMBL1723029 0.76 HPGD (0.50) HSD17B10SMN1; SMN2NPC1RAB9ACA2
Bromide SCHEMBL28377539 0.76 HPGD (0.50) HSD17B10SMN1; SMN2NPC1RAB9ACA2
SCHEMBL23222140 0.76 HSD11B1 (0.47) HSD11B1RARBMAOBRARARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 — — US disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 — — US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 — — EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 — — US disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 — — US disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO HSD11B1 3045/4885RARB 1854/4885TRPV1 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback